10-Q: Athira Pharma Reports Q1 2024 Results, Provides Update on Clinical Programs and Financial Position

Athira Pharma's Q1 2024 report details a net loss of $26.3 million, ongoing clinical trials for fosgonimeton, and sufficient cash to fund operations for at least the next 12 months.

Summary

• Athira Pharma reported a net loss of $26.3 million for the first quarter of 2024, compared to a net loss of $27.8 million for the same period in 2023.
• The company's cash, cash equivalents, and investments totaled $122.1 million as of March 31, 2024.
• Research and development expenses were $21.2 million for both the three months ended March 31, 2024 and 2023.
• General and administrative expenses decreased to $6.5 million in Q1 2024 from $8.5 million in Q1 2023.
• The company estimates its current cash, cash equivalents, and investments will fund operations for at least the next 12 months.
• Athira is continuing its Phase 2/3 LIFT-AD clinical trial for fosgonimeton, with topline results expected in the second half of 2024.
• The company has an at-the-market equity offering facility to sell up to $75 million of common stock, but has not yet sold any shares under this program.
• Athira is also involved in ongoing legal proceedings, including securities class action and shareholder derivative actions.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has sufficient cash for the next 12 months and is progressing with its clinical trials, it continues to incur significant losses and faces substantial risks, including ongoing litigation and the uncertainty of clinical trial outcomes. The lack of revenue and reliance on future funding also contribute to a negative sentiment.

Positives

• The company's net loss decreased slightly compared to the same quarter last year.
• Athira has sufficient cash reserves to fund operations for at least the next 12 months.
• General and administrative expenses decreased by $2 million year-over-year.
• The company is progressing with its LIFT-AD clinical trial, with topline results expected in the second half of 2024.

Negatives

• The company continues to incur significant losses, with a net loss of $26.3 million for the quarter.
• Research and development expenses remain high at $21.2 million for the quarter.
• The company is involved in ongoing legal proceedings, which could result in substantial costs and divert management's attention.

Risks

• The company is a late clinical-stage biopharmaceutical company with a limited operating history.
• The ability to generate revenue and achieve profitability depends significantly on the company's ability to achieve a number of objectives.
• The development of fosgonimeton may never lead to a marketable product.
• The company's approach to targeting neurotrophic factors through the use of small molecules is based on a novel therapeutic approach, which exposes the company to unforeseen risks.
• The company has limited data from its Phase 1a/1b and Phase 2 clinical trials to date, and cannot be certain that future trials will yield data in support of the safety, efficacy and tolerability of its drug candidates.
• The company has concentrated its research and development efforts on the treatment of central and peripheral nervous system degenerative disorders, a field that has seen very limited success in product development.
• The company is and may in the future be subject to claims, lawsuits, arbitration proceedings, government investigations and other legal, regulatory and administrative proceedings and face potential liability and expenses related thereto, which could have a material adverse effect on its business, operating results and financial condition.
• Any topline, interim, initial, or preliminary data from the company's clinical trials that it announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of early, smaller-scale preclinical studies and clinical trials with a single or few clinical trial sites may not be predictive of eventual safety or effectiveness in large-scale potentially pivotal clinical trials across multiple clinical trial sites.
• The company may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all.
• The company's success depends on its ability to protect its intellectual property and its proprietary technologies.
• The company faces significant competition, and if its competitors develop and market technologies or products more rapidly than it does or that are more effective, safer, or less expensive than the drug candidates it develops, its commercial opportunities will be negatively impacted.
• The company may expend its limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• The loss of any of the company's key personnel could significantly harm its business, results of operations and competitive position.
• The company has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future.
• The company will require substantial additional funding to finance its operations, complete the development and commercialization of fosgonimeton, and develop and commercialize other and future drug candidates. If it is unable to raise this funding when needed, it may be forced to delay, reduce, or eliminate its drug product development programs or other operations.
• The regulatory approval processes of the U.S. Food and Drug Administration, or FDA, and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If the company is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its drug candidates, it will not be able to commercialize, or will be delayed in commercializing, its drug candidates, and its ability to generate revenue will be materially impaired.
• The company relies on third parties to conduct its nonclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, it may not be able to obtain regulatory approval of or commercialize its drug candidates.
• Even if approved, the company's drug candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
• The company has never commercialized a drug candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any drug products on its own or together with suitable collaborators.
• If the company experiences delays or difficulties in the enrollment or retention of patients in clinical trials, its regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.
• Intellectual property discovered or developed through government funded programs may be subject to federal regulations such as march-in rights, certain reporting requirements and a manufacturing preference for U.S.-based companies. Compliance with such regulations may limit the company's exclusive rights and limit its ability to contract with non-U.S. manufacturers, which could adversely affect its ability to successfully develop and commercialize its drug products.
• The market price of the company's common stock has been and may continue to be volatile, which could result in substantial losses for investors.
• The company and certain of its directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert management's attention.
• Actions by activist stockholders have in the past been, and may in the future be, disruptive and could cause uncertainty about the strategic direction of the company's business.

Future Outlook

The company expects to report topline LIFT-AD results in the second half of 2024 and estimates that its existing cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months following the date of this report.

Management Comments

• Based upon the Company's current operating plan, it estimates that its $122.1 million of cash, cash equivalents and investments at March 31, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the 12 months following the date of this report.

Industry Context

The company is operating in the challenging field of neurodegenerative disease drug development, where success rates are historically low. The company faces competition from both large pharmaceutical companies and emerging biotechnology companies, some of whom have greater resources and more advanced programs.

Comparison to Industry Standards

• Athira's R&D spending is typical for a clinical-stage biotech company, but its cash burn rate is high, requiring continued fundraising.
• Compared to companies like Biogen and Eli Lilly, which are also developing Alzheimer's treatments, Athira is smaller and has fewer resources.
• The company's reliance on third-party manufacturers is common in the biotech industry, but it introduces risks related to supply chain and quality control.
• The ongoing legal proceedings are a significant risk factor, which is not uncommon for companies in the biotech sector, but the scale of the litigation is substantial.
• The company's cash runway of 12 months is typical for a company at this stage, but it will need to raise additional capital to continue its clinical programs.

Legal Proceedings

• The company is involved in ongoing legal proceedings, including securities class action and shareholder derivative actions.
• The company recorded a legal settlement expense of $10.0 million in operating expenses in the fourth quarter of 2022 and an accrued liability of $10.0 million on the accompanying condensed consolidated balance sheets.
• The company recorded an insurance recovery of $1.6 million in operating expenses in the fourth quarter of 2023 and an insurance recovery receivable of $1.6 million on the accompanying condensed consolidated balance sheets.
• The company received a Civil Investigative Demand from the Civil Division of the Department of Justice.
• The company received a subpoena from the SEC seeking documents and information relating to the company's former chief executive officer's alterations of images in certain research papers.
• The SEC concluded its investigation without any enforcement action against the company.

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential equity offerings.
• Employees may experience uncertainty due to ongoing legal proceedings and potential strategic changes.
• Patients may benefit from the development of new treatments for neurodegenerative diseases, but clinical trial outcomes are uncertain.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company expects to report topline LIFT-AD results in the second half of 2024.
• The company will continue to advance fosgonimeton and other drug candidates through preclinical studies and clinical trials.
• The company will continue the open label extension of the ACT-AD and LIFT-AD trials.
• The company will continue to seek regulatory approval for any drug candidates that successfully complete clinical trials.
• The company will continue to establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which it may obtain marketing approval.

Key Dates

Keywords

Athira Pharma, fosgonimeton, Alzheimer's disease, clinical trials, biopharmaceutical, neurodegenerative disorders, LIFT-AD, ATH-1017, ATH-1020, research and development